Literature DB >> 9705086

The cysteine of the cytoplasmic tail of glucose-dependent insulinotropic peptide receptor mediates its chronic desensitization and down-regulation.

C C Tseng1, X Y Zhang.   

Abstract

The glucose-dependent insulinotropic peptide receptor (GIP-R) is a member of G-protein-coupled, seven transmembrane-spanning receptors. Recent studies have shown that elevated serum GIP level in diabetic patients may induce chronic desensitization of the GIP-R, and that this mechanism could contribute to impaired insulin secretion. The cellular basis of down-regulation and chronic desensitization of GIP-R is unclear. To explore the role of the carboxyl terminus of the GIP-R in mediating these processes, five truncated GIP-Rs (T395, T399, T420, T431, T455) were created to delete consecutive serines from the carboxyl end. All mutants except T395 exhibit an identical ligand-binding affinity to the WT receptor. The T395 mutant, which had the entire carboxyl tail removed, does not bind to ligand. Down-regulation and desensitization was assessed by measuring the receptor number and the ability of agonist-induced cAMP or [Ca2+] generation after pre-exposure to 10(-7) M GIP for 24 h. The wild-type (WT) and T421, T431, T455 mutant GIP-Rs are maximally down-regulated by GIP preincubation, whereas T399 mutant does not, indicating that the sequence between amino acids 399 and 420 is critical for this process. Mutation analysis of this area by alanine scanning mutagenesis reveals two critical residues: serine 406 and cysteine 411. Replacement of serine 406 with arginine (S406R) or alanine (S406A) partly attenuates agonist-induced down-regulation and desensitization. In contrast, mutation of the cysteine 411 to glycine (C411G) or alanine (C411A) markedly attenuates both processes. Mutant SCRG, in which both serine 406 and cysteine 411 are mutated, behaves similar to C411G or C4111A. The data suggest that chronic desensitization and down-regulation of the GIP-R may be mediated by similar mechanisms, and that the cysteine in the carboxyl terminus plays an essential role in regulating both processes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9705086     DOI: 10.1016/s0303-7207(98)00061-6

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  4 in total

Review 1.  Plasticity of the beta cell insulin secretory competence: preparing the pancreatic beta cell for the next meal.

Authors:  Simon A Hinke; Karine Hellemans; Frans C Schuit
Journal:  J Physiol       Date:  2004-06-04       Impact factor: 5.182

2.  Discovery of dual-action membrane-anchored modulators of incretin receptors.

Authors:  Jean-Philippe Fortin; Daniel Chinnapen; Martin Beinborn; Wayne Lencer; Alan S Kopin
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240

3.  A cross-platform approach identifies genetic regulators of human metabolism and health.

Authors:  Luca A Lotta; Maik Pietzner; Isobel D Stewart; Laura B L Wittemans; Chen Li; Roberto Bonelli; Johannes Raffler; Emma K Biggs; Clare Oliver-Williams; Victoria P W Auyeung; Jian'an Luan; Eleanor Wheeler; Ellie Paige; Praveen Surendran; Gregory A Michelotti; Robert A Scott; Stephen Burgess; Verena Zuber; Eleanor Sanderson; Albert Koulman; Fumiaki Imamura; Nita G Forouhi; Kay-Tee Khaw; Julian L Griffin; Angela M Wood; Gabi Kastenmüller; John Danesh; Adam S Butterworth; Fiona M Gribble; Frank Reimann; Melanie Bahlo; Eric Fauman; Nicholas J Wareham; Claudia Langenberg
Journal:  Nat Genet       Date:  2021-01-07       Impact factor: 41.307

4.  Agonist-induced membrane nanodomain clustering drives GLP-1 receptor responses in pancreatic beta cells.

Authors:  Teresa Buenaventura; Stavroula Bitsi; William E Laughlin; Thomas Burgoyne; Zekun Lyu; Affiong I Oqua; Hannah Norman; Emma R McGlone; Andrey S Klymchenko; Ivan R Corrêa; Abigail Walker; Asuka Inoue; Aylin Hanyaloglu; Jak Grimes; Zsombor Koszegi; Davide Calebiro; Guy A Rutter; Stephen R Bloom; Ben Jones; Alejandra Tomas
Journal:  PLoS Biol       Date:  2019-08-20       Impact factor: 8.029

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.